UK markets closed

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
91.30+0.01 (+0.01%)
At close: 04:00PM EDT
91.90 +0.60 (+0.66%)
After hours: 07:58PM EDT

Novo Nordisk A/S

Novo Alle 1
Bagsvaerd 2880
45 44 44 88 88

Full-time employees59,337

Key executives

NameTitlePayExercisedYear born
Mr. Lars Fruergaard JorgensenPres, CEO & Member of Management Board4.61MN/A1966
Mr. Karsten Munk KnudsenExec. VP, CFO & Member of the Management Board1.83MN/A1971
Mr. Henrik Ehlers WulffExec. VP of Product Supply, Quality & IT and Member of the Management Board1.84MN/A1970
Ms. Camilla SylvestExec. VP of Commercial Strategy & Corp. Affairs and Member of the Management Board1.8MN/A1972
Dr. Martin Holst LangeExec. VP of Devel. & Member of the Management Board1.74MN/A1970
Dr. Marcus Schindler Ph.D.EVP of Research & Early Devel., Chief Scientific Officer & Member of the Management Board1.74MN/A1966
Mr. Maziar Mike DoustdarExec. VP of International Operations & Member of the Management BoardN/AN/A1970
Mr. Douglas J. LangaExec. VP of North America Operations & Member of Management BoardN/AN/A1966
Mr. Ludovic HelfgottExec. VP, Head of Rare Disease & Member of Management BoardN/AN/A1974
Ms. Tania SabroeExec. VP of Global People & Organisation and Member of Management BoardN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Corporate governance

Novo Nordisk A/S’s ISS governance QualityScore as of 1 September 2023 is 2. The pillar scores are Audit: 2; Board: 3; Shareholder rights: 10; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.